Filing Details
- Accession Number:
- 0001562180-22-007125
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-10-07 16:05:22
- Reporting Period:
- 2022-10-06
- Accepted Time:
- 2022-10-07 16:05:22
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1395937 | Syndax Pharmaceuticals Inc | SNDX | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1314596 | Keith Katkin | C/O Syndax Pharmaceuticals, Inc. 35 Gatehouse Drive, Building D, Floor 3 Waltham MA 02451 | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-10-06 | 20,782 | $7.88 | 52,782 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-10-06 | 20,782 | $25.90 | 32,000 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2022-10-06 | 9,117 | $8.93 | 41,117 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-10-06 | 9,117 | $25.90 | 32,000 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options (Right to buy) | Disposition | 2022-10-06 | 9,117 | $0.00 | 9,117 | $8.93 |
| Common Stock | Stock Options (Right to buy) | Disposition | 2022-10-06 | 20,782 | $0.00 | 20,782 | $7.88 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2028-05-23 | No | 4 | M | Direct | |
| 0 | 2029-06-10 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 73,000 options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested.
- The sale prices ranged from $25.0000 to $26.4600.
- This option is fully vested.
Billionaire Hedge Funds
